Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Conditions
Keywords
soft tissue sarcoma, aldoxorubicin, ifosfamide, mesna, phase 1, INNO-206
Brief summary
This is a Phase 1 open-label study to study the safety and activity of aldoxorubicin with ifosfamide/mesna in subjects with metastatic, advanced, unresectable soft tissue sarcoma.
Interventions
DRUG170 mg/m2 aldoxorubicin
administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
Sponsors
ImmunityBio, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age between 15-80 years, male or female. 2. Adjuvant or neoadjuvant chemotherapy (including doxorubicin) allowed if no tumor recurrence for at least 12 months since the last measurement, beginning or end of last chemotherapy. 3. Histologically or cytologically confirmed, locally advanced, unresectable, and/or metastatic soft tissue sarcoma (including rhabdomyosarcoma, Ewing's sarcoma and mixed mesodermal sarcoma), chondrosarcoma or osteosarcoma of intermediate or high grade and gastrointestinal stromal tumors (GIST) (only in subjects that have progressed after receiving treatment with imatinib and sunitinib). 4. Capable of providing informed consent and complying with trial procedures. 5. ECOG performance status 0-2. 6. Life expectancy \>12 weeks. 7. Measurable tumor lesions according to RECIST 1.1 criteria. 8. Women must not be able to become pregnant (eg post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. (Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.) 9. Males and their female partner(s) of child-bearing potential must use 2 forms of effective contraception (see Inclusion 8 plus condom or vasectomy for males) from the last menstrual period of the female partner during the study treatment and for 6 months after the final dose of study treatment. 10. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. 11. Geographic accessibility to the site that ensures the subject will be able to keep all study-related appointments.
Exclusion criteria
1. Prior chemotherapy unless for adjuvant or neoadjuvant therapy with no tumor recurrence for at least 12 months. 2. Prior exposure to \>3 cycles or 225 mg/m2 of doxorubicin or Doxil®. 3. Palliative surgery and/or radiation treatment less than 30 days prior to enrollment. 4. Exposure to any investigational agent within 30 days of enrollment. 5. Current Stage 1 or 2 soft tissue sarcomas. 6. Current evidence/diagnosis of alveolar soft part sarcoma, dermatofibrosarcoma, Kaposi's sarcoma, clear cell sarcomas and unresectable low grade liposarcomas. 7. Central nervous system metastasis if symptomatic. 8. History of other malignancies except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix unless documented free of cancer for ≥ 5 years. 9. Laboratory values: Screening serum creatinine \>1.5x upper limit of normal (ULN), alanine aminotransferase (ALT) \> 3 × ULN or \>5 × ULN if liver metastases are present, total bilirubin \>3 × ULN, absolute neutrophil count \<1,500/mm3, platelet concentration \<100,000/mm3, hematocrit level \<25% for females or \<27% for males, albumin \<2 gm/dL, coagulation tests (prothrombin time \[PT\], partial thromboplastin time \[PTT\], International Normalized Ratio \[INR\]) \>1.5 × ULN. 10. Clinically evident congestive heart failure \> class II of the New York Heart Association (NYHA) guidelines.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events in Participants | Treatment was planned to continue until tumor progression is observed, subject asks to withdraw, or unacceptable toxicity occurs (up to 766 days). | The primary objective of this study is to determine the preliminary safety of administration of aldoxorubicin in combination with ifosfamide in subjects with metastatic, locally advanced, or unresectable soft tissue sarcoma as measured by the frequency and severity of adverse events (AEs). The following assessments were used to determine if subjects had adverse events: * vitals signs (systolic/diastolic blood pressure, pulse, respiration, temperature, weight, and body surface area) * physical examination * laboratory tests (chemistry, hematology, urinalysis, anion gap) additionally, the following scans were performed to determine adverse events: * ECHO / MUGA * ECG |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 170 mg/m^2 Aldoxorubicin 170 mg/m\^2 aldoxorubicin: administered at 170 mg/m\^2 plus 1 gm/m\^2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days | 6 |
| 250 mg/m^2 Aldoxorubicin 250 mg/m\^2 aldoxorubicin: administered at 250 mg/m\^2 plus 1 gm/m\^2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days | 64 |
| Total | 70 |
Baseline characteristics
| Characteristic | 170 mg/m^2 Aldoxorubicin | 250 mg/m^2 Aldoxorubicin | Total |
|---|---|---|---|
| Age, Continuous | 40 years STANDARD_DEVIATION 14.14 | 51.5 years STANDARD_DEVIATION 15.05 | 50.5 years STANDARD_DEVIATION 15.22 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 24 Participants | 25 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 40 Participants | 45 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Histologically or cytologically confirmed, locally advanced, unresectable, and/or metastatic STS | 6 Participants | 64 Participants | 70 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 7 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 56 Participants | 61 Participants |
| Sex: Female, Male Female | 1 Participants | 28 Participants | 29 Participants |
| Sex: Female, Male Male | 5 Participants | 36 Participants | 41 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 16 / 64 |
| other Total, other adverse events | 6 / 6 | 64 / 64 |
| serious Total, serious adverse events | 3 / 6 | 31 / 64 |
Outcome results
Primary
Number of Adverse Events in Participants
The primary objective of this study is to determine the preliminary safety of administration of aldoxorubicin in combination with ifosfamide in subjects with metastatic, locally advanced, or unresectable soft tissue sarcoma as measured by the frequency and severity of adverse events (AEs). The following assessments were used to determine if subjects had adverse events: * vitals signs (systolic/diastolic blood pressure, pulse, respiration, temperature, weight, and body surface area) * physical examination * laboratory tests (chemistry, hematology, urinalysis, anion gap) additionally, the following scans were performed to determine adverse events: * ECHO / MUGA * ECG
Time frame: Treatment was planned to continue until tumor progression is observed, subject asks to withdraw, or unacceptable toxicity occurs (up to 766 days).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 170 mg/m^2 Aldoxorubicin | Number of Adverse Events in Participants | 6 Participants |
| 250 mg/m^2 Aldoxorubicin | Number of Adverse Events in Participants | 64 Participants |